Clinical Trials Logo

Clinical Trial Summary

Hibiscus sabdariffa tea is commonly used all over the world by healthy individual but the tea is also employed by patients in the management of chronic diseases such as hypertension diabetes, high cholesterol, liver disease etc. Several studies in humans and animal have proved the efficacy of Hibiscus sabdariffa tea in lowering blood pressure, blood glucose level and serum total cholesterol. But no study exists on the effect of daily consumption of this tea on blood pressure, blood glucose, total cholesterol and other biochemical and hematological parameters in healthy humans. Hence this study.


Clinical Trial Description

Several studies have been carried out on the effect of the water beverage of Hibiscus sabdariffa, most focus on hypertensive patients, diabetic patients and obese patient and some studies investigated the hypolipidemic a effect of the water beverage of Hibiscus sabdariffa as well as its effect on haematological parameters but mice were used for these studies. Little or no investigation has been done to assess the safety of daily consumption of this water beverage of hibiscus sabdariffa on humans.

Hence, this study aims at investigating the safety in the daily consumption of Zobo in humans, monitoring lipid profile, blood pressure, blood glucose, body mass index and haematological parameters such as haematocrit, haemoglobin, total white blood cells and also hepatic indices. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04339283
Study type Interventional
Source University of Ibadan
Contact
Status Completed
Phase N/A
Start date September 1, 2019
Completion date October 30, 2019

See also
  Status Clinical Trial Phase
Completed NCT00765427 - Safety and Tolerability of Retinoid QLT091001 in Healthy Volunteers Phase 1
Completed NCT00813670 - Single and Multiple Ascending Dose Safety Study of XPF-001 in Healthy Volunteers Phase 1
Completed NCT02219438 - Continuous Adductor Canal Nerve Blocks: Relative Effects of a Basal Infusion v. Hourly Bolus Doses Phase 4